October 3rd 2023
The degree of toxicity following pediatric ingestion of THC was correlated to the dose of THC, as ingestions of 1.7 mg/kg or more was predictive of severe and prolonged toxicity, according to a study published in Pediatrics.
Discussing the upcoming RSV season, new tools, and vaccine hesitancy
September 27th 2023In collaboration with Contemporary Pediatrics, Contemporary OB/GYN, and Contagion, Tina Tan, MD, FAAP, FIDSA, FPIDS, discusses the benefits of having new tools to fight RSV in infants, potential vaccine hesitancy, and RSV trends currently being observed.
Evaluating pediatric ED readiness and racial, ethnic disparities in mortality
September 27th 2023Peter C. Jenkins, MD, MSc, details his study recently published in Jama Network Open, evaluating associations between pediatric emergency department readiness and mortality, and if children of all races benefited equitably.
CDC recommends Pfizer’s maternal RSV vaccine to protect newborns
September 25th 2023Ahead of the first fall and winter virus seasons in which vaccines are available for COVID-19, influenza, and respiratory syncytial virus (RSV), the Centers for Disease Control and Prevention is recommending Pfizer’s maternal vaccine to protect newborns from severe RSV illness.
Arcutis submits roflumilast 0.15% sNDA for AD in children 6 years and up
September 21st 2023Positive topline results from a pair of identical phase 3 trials support the submission of a supplemental New Drug Application to the FDA for Arcutis Biotherapeutics’ roflumilast cream 0.15%, a once-daily topical to treat mild to moderate atopic dermatitis (AD) in children 6 years or older.
Roflumilast cream 0.05% safe, effective for children aged 2 to 5 years with atopic dermatitis
September 20th 2023Based on recent positive phase 3 results, Arcutis Biotherapeutics,. intends to submit a supplemental New Drug Application with the FDA for roflumilast cream 0.05% to treat mild to moderate atopic dermatitis in children aged 2 to 5 years.
FDA issues CRL for neffy nasal spray to treat allergic reactions, requests more research
September 20th 2023The FDA issued the Complete Response Letter (CRL) based on the request for a completed pharmacokinetic/pharmacodynamic study to assess how repeat doses of the epinephrine nasal spray compare to repeat doses of an epinephrine injection product. ARS Pharma is set to file a Formal Dispute Resolution Request to appeal the CRL.
Associations between prenatal metal mixture exposure and negative infant outcomes
September 19th 2023Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.
Poll: Majority of parents concerned about bad air quality, impact on child's health
September 19th 2023According to a recent C.S. Mott Children’s Hospital National Poll on Children’s Health, the recent wildfires and extreme weather events that are creating poor or unhealthy air quality are also causing concern for parents in regards to their children's health.